Link Biologics

Link Biologics is a UK-based biotechnology company focused on developing innovative biological therapies for inflammatory and degenerative diseases, with a primary emphasis on osteoarthritis. The company's lead asset, Link_TSG6, is a recombinant version of the human TSG-6 protein, which plays a crucial role in regulating inflammation and protecting joint tissues. By leveraging the natural tissue-protective properties of TSG-6, Link Biologics aims to provide disease-modifying treatments that address the underlying causes of joint degeneration rather than just managing symptoms. The company is currently advancing its lead program through pre-clinical development toward first-in-human clinical trials. Link Biologics was spun out from the University of Manchester, building on decades of research into the structure and function of the TSG-6 protein.